Zosano reports positive results for hypoglycemia PhII; Portola drug betrixaban gains fast-track status;

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Analysts, experts write off Merck's huge anacetrapib PhIII. Report | Follow @JohnCFierce

@DamianFierce: Entirely baffled by 's business model. More | Follow @DamianFierce

> Fremont, CA-based Zosano reported that its Phase II study of its transdermal ZP-Glucagon patch for severe hypoglycemia came through with positive results. The biotech is considering mounting a pivotal study next year. Release

> The FDA has granted Portola Pharmaceuticals ($PTLA) fast-track status for the anticoagulant betrixaban. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @FierceMedDev

@VarunSaxena2: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More | Follow @VarunSaxena2

@EmilyWFierce: Report: AstraZeneca funnels billions into Dutch tax-avoidance scheme. FiercePharma story | Follow @EmilyWFierce

> Is Turing illegally thwarting generic copycats? New York antitrust squad wants to know. More

> J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article

Pharma News

@FiercePharma: Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article | Follow @CarlyHFierce

> Former Pfizer chemist and Zoloft co-developer Ken Koe dies at 90. News

> Novo Nordisk chief Sørensen tops world's-best CEO ranking. More

Drug Delivery News

> Study finds EpiPens can injure children, recommends improved technique and design. More

> Russian Academy: Combining drugs with ionic liquids can up the solubility, cut polymorphism. News

> Medicines Co. enters Japanese market, handing over license to transdermal pain patch. Story

> OptiNose bags $30M in VC financing as partner Otsuka barrels toward its second PDUFA date. Article

> 3M takes on blood-brain barrier with Impel Neuropharma nasal drug delivery alliance. Report

Pharma Manufacturing News

> Pests again figure into issues in FDA warning letter to Indian API maker. More

> Cipla's new U.S. plant received Form 483 just ahead of deal. News

> CPhI report predicts growth in outsourcing for sterile injectables. More

> Aurobindo to expand India API plant fourfold. Story

> Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home. Article

Pharma Asia News

> HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen. Story

> CIMB says Malaysian pharmas have scope to adjust to TPP changes. Report

> China's Innovent Biologics deepens pact with Eli Lilly on immuno-oncology. Article

> Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. Item

> Hong Kong drugstores attract Chinese customers for cancer, hep C drugs. More

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.